Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIAGARA: Durvalumab + Chemotherapy in Muscle-Invasive Bladder Cancer
NCT03732677Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of durvalumab in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Pathologic Complete Response at 6 months and Event-free Survival at 48 months. Started Nov 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03732677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732677.